



Tehran University of Medical  
Sciences Publication  
<http://tums.ac.ir>

## Iran J Parasitol

Open access Journal at  
<http://ijpa.tums.ac.ir>



Iranian Society of Parasitology  
<http://isp.tums.ac.ir>

### Original Article

## Identification of *Entamoeba* Species in Diarrheal Samples Using Sequence Analysis and Nested Multiplex PCR

\*Zuhair Mohammed Abed <sup>1</sup>, Raghda Mahmood Hamad <sup>2</sup>

1. Salah Al-Din Education Directorate, Ministry of Education, Tikrit, Iraq
2. Department of Biology, College of Education for Pure Sciences, University of Tikrit, Tikrit, Iraq

Received 10 Dec 2024  
Accepted 19 Mar 2025

#### Keywords:

*Entamoeba* spp.;  
Diarrhea samples;  
Nested multiplex PCR assay

#### \*Correspondence Email:

[zuhairmohammedabed@gmail.com](mailto:zuhairmohammedabed@gmail.com)

#### Abstract

**Background:** Among the many *Entamoeba* species that infect humans, only *Entamoeba histolytica* is considered pathogenic, being responsible for amoebiasis or amoebic dysentery.

**Methods:** Between June and October 2022, a total of 106 stool samples were collected from children under six years of age presenting with diarrhea at Paiji Hospital in the city of Paiji, Iraq. DNA was extracted from all stool specimens to detect the presence of parasitic organisms.

**Results:** Of the 106 fecal samples, 4 (3.7%) tested positive for *Entamoeba* spp. using an initial PCR amplification targeting approximately 900 bp of the 18S rRNA gene. Among these, only one sample tested positive for *E. histolytica* using a nested multiplex PCR assay. In this study, neither *E. moshkovskii* nor *E. dispar* was detected. Sequence analysis of the partial 18S rRNA gene revealed that 0.9% of samples were positive for *E. histolytica*, while 2.8% were positive for *E. coli*. The sequences were deposited in GenBank under the accession numbers OP868733.1 for *E. histolytica* and OP868730.1, OP868731.1, and OP868732.1 for *E. coli*.

**Conclusion:** Children were infected with different species of *Entamoeba*. Molecular methods are essential for distinguishing between *Entamoeba* species due to their significance in accurate diagnosis and appropriate treatment strategies.



Copyright © 2025 Mohammad Abed et al. Published by Tehran University of Medical Sciences.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.

(<https://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited

## Introduction

The protozoan *Entamoeba* spp. includes various species, six of which inhabit the gastrointestinal tract: *E. coli*, *E. histolytica*, *E. moshkovskii*, *E. dispar*, *E. polecki*, and *E. hartmanni* (1). Among these amoebae, only *E. histolytica* is considered pathogenic to humans and is responsible for amoebiasis or amoebic dysentery (2,3). The most common symptoms of this disease include diarrhea, cramping, abdominal pain, low-grade fever, colitis, fatigue, stools containing mucus and blood, ulcers, and weight loss (4,5).

*E. coli* is considered a non-pathogenic protozoan that resides in the human intestinal tract (6). However, in severe *E. coli* infections, affected individuals may experience gastritis and indigestion. In general, symptoms of amoebiasis caused by *E. coli* include flatulence, loose stools, and, in rare cases, colicky abdominal pain (7).

The life cycle of *Entamoeba* spp. is similar across species. It begins with the ingestion of parasite cysts through food or drink contaminated with feces. Once the cysts reach the small intestine, excystation occurs, and trophozoites emerge. The trophozoites migrate to the large intestine and attach to the mucosal layer (8).

Microscopic examination has been widely used in diagnosing amoebic infections; however, it is both insensitive and unreliable for distinguishing between infections caused by *E. histolytica* and non-pathogenic *Entamoeba* spp. (9). It is essential to differentiate between morphologically similar pathogenic species, such as *E. histolytica*, and non-pathogenic species, including *E. dispar*, *E. moshkovskii*, *E. polecki*, *E. coli*, and *E. hartmanni* (10,11).

Molecular methods based on genomic DNA amplification have proven to be highly sensitive and reliable for distinguishing between *Entamoeba* species (12).

## Materials and Method

### Sample Collection

A total of 106 fresh stool samples were collected from Pajji Hospital (city of Pajji, Iraq)

from diarrheal children under six years of age during the period from June to October 2022. All samples were placed in sterile containers and transferred to the parasitology laboratory at the University of Tikrit. The samples were stored at -20°C for molecular analysis.

### Molecular Method

DNA was extracted from all stool samples to detect *Entamoeba* spp. Genomic DNA extraction was performed using the Stool DNA Extraction Kit (Bioneer, Korea) according to the manufacturer's instructions. The purified DNA samples were stored at -20°C for subsequent PCR amplification.

### Nested Multiplex PCR Assay

The first PCR amplified approximately 900 bp of the 18S rRNA gene using specific primers: E-1 forward (5'-TAAGATGCACGAGAGCGAAA-3') and E-2 reverse (5'-TACAAAGGGCAGGGACGTA-3') for the detection of *Entamoeba* spp. (13). Each first reaction was performed in a 20 µl volume, containing 1 µl of each primer and 3 µl of template DNA. The thermal profile included one cycle of 95°C for 5 minutes to denature the double-stranded DNA, followed by 30 cycles of 94°C for 30 seconds (denaturation), 58°C for 30 seconds (annealing), and 72°C for 30 seconds (extension), with a final extension at 72°C for 5 minutes. PCR products were separated using 1.5% agarose gel electrophoresis and visualized.

The second PCR amplified 439 bp, 174 bp, and 553 bp for the detection of *E. histolytica*, *E. dispar*, and *E. moshkovskii*, respectively, using three pairs of primers: EH-1 (5'-AAGCATTGTTTCTAGATCTGAG-3') and EH-2 (5'-AAGAGGTCTAACCGAAATTAG-3'); ED-1 (5'-TCTAATTTCGATTAGAAGCTCT-3') and ED-2 (5'-TCCCTACCTATTAGACATAGC-3'); and

MOS-1 (5'-GAAACCAAGAGTTTCACAAC-3') and MOS-2 (5'-CAATATAAGGCTTGGATGAT-3'). Each second reaction was performed in a 20 µl volume, containing 1 µl of each primer, 3 µl of the first PCR product, and water. The thermal profile for the second PCR included 35 cycles at 94°C for 30 seconds (denaturation), 55°C for 30 seconds (annealing), and 72°C for 30 seconds (extension), with a final extension at 72°C for 5 minutes. PCR products were separated using 1.5% agarose gel electrophoresis and visualized.


### Sequencing

The 18S rRNA sequences were compared with sequences in the NCBI nucleotide database using BLAST for analysis and identifica-


tion. Evolutionary analyses were conducted using MEGA6 software (14).

### Results

Of the 106 fecal samples analyzed, 4 (3.7%) tested positive for *Entamoeba* spp. by the first PCR amplification of approximately 900 bp of the 18S rRNA gene (Fig. 1). Among these, only one sample (0.9%) was positive for *E. histolytica* using the nested multiplex PCR assay. Neither *E. dispar* nor *E. moshkovskii* was identified in the current study (Fig. 2). Sequence analysis of the partial 18S rRNA gene revealed that 4 samples were positive, including *E. histolytica* (0.9%) and *E. coli* (2.8%). The sequences were deposited in GenBank under the accession numbers OP868733.1 for *E. histolytica* and OP868730.1, OP868731.1, and OP868732.1 for *E. coli* (Fig. 3).




**Fig. 1:** Agarose gel electrophoresis for the product first PCR Amplify about 900bp of 18s rRNA gene. lanes 1,3,5,6 positive for *Entamoeba* spp.



**Fig. 2:** Agarose gel electrophoresis for the product second PCR amplifying the 439bp, for the detection of the *E. histolytica*. Lane 9 positive for *E. histolytica*.

**Table 1:** prevalence of species *Entamoeba* in diarrhea children

Collected	First PCR		Nested multiplex PCR		Sequencing assay	
	Species	Positive sample %	Species	Positive sample %	Species	Positive sample %
106						
	<i>Entamoeba</i> spp.	4(3.7%)	<i>E. histolytica</i>	1(0.9%)	<i>E. histolytica</i>	1(0.9)
					<i>E. coli</i>	3(2.8)



**Fig. 3:** Phylogenetic tree of *Entamoeba* spp identified in the present study and reference sequences from Gen Bank

**Table 2:** Genetic rapprochement of 18s rRNA for the isolate of *Entamoeba* spp. in the present study in comparison with those obtained in the Genbank.

	Accession	Country	Source	Isolation source	Compatibility %
1.	ID: <a href="#">MW026736.1</a>	Brazil	<i>Entamoeba coli</i>	Homo sapiens	99
2.	ID: <a href="#">FR686364.1</a>	Nigeria	<i>Entamoeba coli</i>	Homo sapiens	99
3.	ID: <a href="#">FR686410.1</a>	Germany	<i>Entamoeba coli</i>	Mandrillus leuco-phaeus	95
4.	ID: <a href="#">MK541025.1</a>	Mexico	<i>Entamoeba coli</i>	Homo sapiens	94
5.	ID: <a href="#">MK541024.1</a>	Argentina	<i>Entamoeba coli</i>	Homo sapiens	94
6.	ID: <a href="#">FR686421.1</a>	Denmark	<i>Entamoeba coli</i>	Homo sapiens	94
7.	ID: <a href="#">AF149915.1</a>	USA	<i>Entamoeba coli</i>	-----	94
8.	ID: <a href="#">MH133210.1</a>	China	<i>Entamoeba coli</i>	Rhesus macaques	94
9.	ID: <a href="#">FR686433.1</a>	Viet Nam	<i>Entamoeba coli</i>	Homo sapiens	90
10.	ID: <a href="#">MH620469.1</a>	Taiwan	<i>Entamoeba coli</i>	-----	89
11.	ID: <a href="#">MK332025.1</a>	Egypt	<i>Entamoeba histolytica</i>	-----	99
12.	ID: <a href="#">KP233837.1</a>	Iraq:Alqadissiyya	<i>Entamoeba histolytica</i>	-----	99
13.	ID: <a href="#">AB426549.1</a>	Japan	<i>Entamoeba histolytica</i>	De Brazza's guenon	99
14.	ID: <a href="#">AB197936.1</a>	China	<i>Entamoeba histolytica</i>	cynomolgus monkey	99
15.	ID: <a href="#">OM780326.1</a>	India	<i>Entamoeba histolytica</i>	Homo sapiens	99
16.	ID: <a href="#">OK576922.1</a>	Peru	<i>Entamoeba histolytica</i>	Blueberries	99
17.	ID: <a href="#">GQ423749</a>	Philippines	<i>Entamoeba histolytica</i>	Macaque	99
18.	ID: <a href="#">AB845673.1</a>	Cameroon	<i>Entamoeba histolytica</i>	Homo sapiens	99
19.	ID: <a href="#">KX528459.1</a>	Iran	<i>Entamoeba histolytica</i>	Homo sapiens	99

## Discussion

The presence of *Entamoeba* spp. in stool samples can be detected using microscopic examination, which primarily relies on mor-

phological characteristics such as the number of nuclei and cyst size. However, misdiagnosis may occur when using microscopy due to overlapping morphological characteristics among different *Entamoeba* species (15).



Therefore, molecular methods were employed in this study because of their higher sensitivity and specificity in diagnosing *Entamoeba* spp.

In our study, the prevalence of *Entamoeba* spp. in humans was 3.7% (Table 1). This result is roughly consistent with that of Mahmood and Bakr (16), who reported a 7.4% infection rate in *Entamoeba* spp. in Erbil. However, our findings showed a much lower prevalence compared to Flaih et al. (17), who recorded an infection rate of 52.5%. The discrepancy in prevalence may be attributed to the timing of sample collection; in the current study, samples were collected during the summer when high temperatures likely reduce the viability of infective stages.

Using nested PCR, our study identified a prevalence rate of *E. histolytica* at 0.9%, while *E. dispar* and *E. moshkovskii* were not detected. In contrast, a study in Erbil reported infection rates of 6% for *E. histolytica*, 4.3% for *E. dispar*, and 0.3% for *E. moshkovskii* (16). Higher infection rates were observed in Thi-Qar, where microscopy and PCR detected *E. histolytica* in 55.5% and *E. dispar* in 30% of cases (18). Additionally, other studies reported *E. histolytica* prevalence rates of 0.14% in western Iran (19) and 7.5% in Kenya (20).

Three isolates of *E. coli* and one of *E. histolytica* were deposited in NCBI according to sequence analysis of the partial 18S rRNA gene, with accession numbers OP868730.1, OP868731.1, and OP868732.1 for *E. coli*, and OP868733.1 for *E. histolytica* (Fig. 3). These isolates showed 89–99% homology with *Entamoeba* spp. sequences recorded in GenBank from Brazil (MW026736.1), Nigeria (FR686364.1), Germany (FR686410.1), Mexico (MK541025.1), Egypt (MK332025.1), Iraq: Al-Qadisiyah (KP233837.1), Japan (AB426549.1), and China (AB197936.1), as well as other countries (Table 2, Fig. 3).

In the current study, sequence analysis of the partial 18S rRNA gene revealed the presence of the commensal *E. coli* in 2.8% of diarrhea samples and *E. histolytica* in 0.9%. The presence of *E. coli* in diarrhea samples may be

due to co-infections with other pathogenic organisms, including bacteria, viruses, and fungi. In a study conducted in Erbil, *E. histolytica* and *E. coli* were detected with infection rates of 51.7% and 51.2%, respectively (21). Another study reported *E. coli* detection in stool samples using nested PCR with an infection rate of 32.7%, compared to 29.1% via microscopy (7). Furthermore, approximately 70% of patients infected with parasites had *E. coli* (22). The prevalence of *E. coli* in random stool samples was 4.6% (23). Additionally, *E. coli* was detected in Sudan with an infection rate of 7.5% (24) and in Brazil at 11.02% (25). Variations in prevalence rates can be attributed to factors such as differences in study populations, geographical locations, socioeconomic conditions, poor sanitation, personal hygiene practices, and overcrowding (26).

## Conclusion

Children are susceptible to infections by both pathogenic *E. histolytica* and non-pathogenic amoebas. Molecular methods are crucial for differentiating between *Entamoeba* species due to their importance in accurate diagnosis and the implications for treatment. This study found a low infection rate of *E. histolytica* compared to *E. coli*, emphasizing the need for enhanced diagnostic techniques to improve disease management and control.

## Conflict of Interest

The authors declare that there is no conflict of interests.

## References

1. Fotadar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. PCR detection of *Entamoeba histolytica*, *Entamoeba dispar*, and *Entamoeba moshkovskii* in stool samples from Sydney, Australia. J Clin Microbiol. 2007; 45(3):1035-7.

2. Paniker CJ. Paniker's textbook of medical Parasitology. JP Medical Ltd; 2017 Sep 14.
3. Uribe-Querol E, Rosales C. Immune response to the enteric parasite *Entamoeba histolytica*. Physiology (Bethesda). 2020; 35(4):244-60.
4. Chowdhury RA, Esiobu N, Meerooff DE, Bloetscher F. Different detection and treatment methods for *Entamoeba histolytica* and *Entamoeba dispar* in water/wastewater: a review. J Environ Prot. 2022; 13(1):126-49.
5. Alyasari HF, Hashim HO, Altaei AH, Al-Shuhaib MB. Identification of serious clinical amebic dysentery cases in the middle Euphrates region of Iraq. J Biol Sci. 2019; 19 (2):148-154.
6. Feng M, Pandey K, Yanagi T, et al. Prevalence and genotypic diversity of *Entamoeba* species in inhabitants in Kathmandu, Nepal. Parasitol Res. 2018; 117:2467-72.
7. Rattaprasert P, Nitatsukprasert C, Thima K, et al. Development of nested pcr for identification of *Entamoeba coli* in human fecal samples. Southeast Asian J Trop Med Public Health. 2022; 53(1):21-36.
8. Begum S, Quach J, Chadee K. Immune evasion mechanisms of *Entamoeba histolytica*: progression to disease. Front Microbiol. 2015; 6:1394.
9. Liu X, Bao G, Yue M, et al. Prevalence and molecular identification of *Entamoeba* spp. in non-human primates in a zoological garden in Nanjing, China. Front Vet Sci. 2022; 9:906822.
10. Gomes TD, Garcia MC, Souza Cunha FD, et al. Differential Diagnosis of *Entamoeba* spp. in Clinical Stool Samples Using SYBR Green Real-Time Polymerase Chain Reaction. ScientificWorldJournal. 2014; 2014:645084.
11. Puebla LE, Núñez-Fernández FA, Nodarse JF, et al. Diagnosis of intestinal protozoan infections in patients in Cuba by microscopy and molecular methods: advantages and disadvantages. J Microbiol Methods. 2020; 179:106102.
12. Soares NM, Azevedo HC, Pacheco FTF, et al. A Cross-Sectional Study of *Entamoeba histolytica*/*dispar*/*moshkovskii* Complex in Salvador, Bahia, Brazil. Biomed Res Int. 2019; 2019:7523670.
13. Khairnar K, Parija SC. A novel nested multiplex polymerase chain reaction (PCR) assay for differential detection of *Entamoeba histolytica*, *E. moshkovskii* and *E. dispar* DNA in stool samples. BMC Microbiol. 2007; 7:47.
14. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013; 30(12):2725-9.
15. Carrero JC, Reyes-López M, Serrano-Luna J, et al. Intestinal amoebiasis: 160 years of its first detection and still remains as a health problem in developing countries. Int J Med Microbiol. 2020; 310(1):151358.
16. Mahmood SA, Bakr HM. Molecular Identification and Prevalence of and in Erbil City, Northern Iraq. Pol J Microbiol. 2020; 69(3):1-10.
17. Flaih MH, Khazaal RM, Kadhim MK, Hussein KR, Alhamadani FA. The epidemiology of amoebiasis in Thi-Qar Province, Iraq (2015-2020): differentiation of *Entamoeba histolytica* and *Entamoeba dispar* using nested and real-time polymerase chain reaction. Epidemiol Health. 2021; 43:e2021034.
18. Ziguer AM, Mahdi DS, Khalaf AK. Molecular detection of *Entamoeba* spp. By using multiplex PCR in Thi-Qar province. Biochem Cell Arch. 2020; 20(2):6363-7.
19. Bahrami F, Haghighi A, Zamini G, et al. Differential detection of *Entamoeba histolytica*, *Entamoeba dispar* and *Entamoeba moshkovskii* in faecal samples using nested multiplex PCR in west of Iran. Epidemiol Infect. 2019;147: e96.
20. Mulinge E, Mbae C, Ngugi B, et al. *Entamoeba* species infection in patients seeking treatment for diarrhea and abdominal discomfort in Mukuru informal settlement in Nairobi, Kenya. Food Waterborne Parasitol. 2021; 23: e00122.
21. Hamad N, Ahmed R. Intestinal parasites among patients attending general central public health laboratory in Erbil city-Iraq during 1998-2004. J Educ Sci. 2011;24(4):79-86.

22. Ngui R, Angal L, Fakhrurrazi SA, et al. Differentiating *Entamoeba histolytica*, *Entamoeba dispar* and *Entamoeba moshkovskii* using nested polymerase chain reaction (PCR) in rural communities in Malaysia. Parasit Vectors. 2012; 5:187.
23. Norouzi P, Mohaghegh MA, Ghorbani M, et al. Investigating the prevalence of intestinal parasites with an emphasis on *Strongyloides stercoralis* infection in hospitalized patients: a regional report from Iran. Ann Parasitol. 2020; 66(3): 365-371.
24. Alsaafin Y, Omer A, Felemban O, et al. Prevalence and Risk Factors of Schistosomiasis in Sudan: A Systematic Review and Meta-Analysis. Cureus. 2024;16(11): e73966.
25. Belchior VLR, Toma HK, Batista KM, et al. Predominance of *Blastocystis* spp., *Entamoeba histolytica* /e.dispar and other protozoan evaluated through classical and molecular diagnostic techniques in two communities of Niterói-rj / Brazil. Braz J Health Rev. 2021; 4(3):11741-11754.
26. Lepore CM, Kamau L, Kanduma E. Molecular Prevalence of *Entamoeba* Species among Diarrheal Patients in Eastern Kenya. Eur J Biol Biotechnol. 2022;3(1):39-46.